Acronym / code: VASCUL-AID / 101080947
Project type: HORIZON Research and Innovation Actions
Realization period: 1. 5. 2023 - 30. 4. 2029.
Project funded by: European Health and Digital Executive Agency
SRO project holder: STICHTING VUMC (VUMC), DE BOELELAAN 1117, AMSTERDAM 1081 HV, Netherlands
  • VINČA Institute of Nuclear Sciences, University of Belgrade
  • ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (AMC), Amsterdam, Netherlands,
  • BRIGHTFISH BE (BFS), Belgium,
  • UNIVERSITEIT TWENTE (UOT), Netherlands,
  • UNIVERSIDADE DO PORTO (FMUP), Portugal,
  • CENTRE HOSPITALIER UNIVERSITAIRE DE NICE (CHUN), NICE, France,
  • STICHTING ALLAI NEDERLAND (ALLAI), AMSTERDAM Netherlands,
  • FACULTY OF MEDICINE, UNIVERSITY OF BELGRADE (UOB), BELGRADE, Serbia,
  • HUS-YHTYMA (HUS), HELSINKI, Finland,
  • UNIVERSITETET I BERGEN (UiB), BERGEN, Norway,
  • MEDIZINISCHE HOCHSCHULE BRANDENBURG CAMPUS GMBH (MHB), NEURUPPIN, Germany,
Principal investigator: Maja Živković
Tamara Đurić-Delić
Principal investigator: dr. Kak Khee Yeung (STICHTING VUMC (VUMC), AMSTERDAM, Netherlands)
Project website: https://vascul-aid.eu/

The aim of VASCUL-AID is to predict the risk of cardiovascular events and progression of the vascular diseases: Abdominal Aortic Aneurysm (AAA) and Peripheral Arterial Disease (PAD) to influence the course of disease improving the patient’s quality of life and care and assisting clinicians to make better-informed decisions involving the patient. To this end, it will deliver a clinically relevant and cost-effective trustworthy AI-driven platform (VASCUL-AID) that integrates multi-source parameters including imaging, proteomic and genomic data as well as life-style patient data from wearables to enable personalized vascular disease management. The VASCUL-AID platform consists of AI risk-prediction tools, a patient communication app and a clinical dashboard to support clinical decision-making. In this project, the aim is to build an EU-wide data infrastructure, to develop an AI-based progression prediction tools for AAA and PAD, to develop criteria according to the COMET initiative to assess the effectiveness of VASCUL-AID, and to clinically test and show proof-of-concept for the VASCUL-AID platform. VASCUL-AID brings together 14 leading organizations consisting of clinical academic centers, institutes, universities and SMEs as well as large industry, patients’ organizations and policy makers that cover the full value chain to enable integration of the platform into clinical practice.